SG&A Efficiency Analysis: Comparing Novartis AG and TG Therapeutics, Inc.

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Novartis AG and TG Therapeutics, Inc. have showcased contrasting strategies in managing these costs.

Novartis AG, a global leader, consistently reported SG&A expenses averaging around $14.5 billion annually from 2014 to 2023. Despite fluctuations, their expenses peaked in 2018, reflecting strategic investments in marketing and administration. In contrast, TG Therapeutics, Inc., a smaller biotech firm, demonstrated a more volatile pattern. Their SG&A expenses surged by over 500% from 2014 to 2023, highlighting aggressive expansion efforts.

This analysis underscores the diverse approaches in SG&A management, with Novartis focusing on steady growth and TG Therapeutics on rapid scaling. Investors and analysts can glean insights into each company's operational priorities and market strategies.